Scientific Program
Bradykinin Symposium
Thursday, 3 September 2026
11:00-12:00
Lunch and Welcome
12:00-12:15
Welcome
Michael Bader | Markus Magerl | Thomas Renné
12:15-13:15
Session I: Bradykinin Basics
12:15-12:45
The Origin of Bradykinin
Sam Robinson
12:45-13:15
Visualizing the Leak: Intravital Imaging of Vascular Permeability
Michael Orlich
13:15-13:45
Coffee Break
13:45-15:15
Session II: Kinin Receptors and Pathophysiology
13:45-14:15
Kinin B1 Receptor as a Neuroimmune Modulator of Cardiovascular Regulation
Srinivas Sriramula
14:15-14:45
Kininogen Knockout Mice
Masaoki Takano
14:45-14:55
OP.01 | From Molecular Design to Functional Hepatology: Stable Kinin Analogs Reveal B1 Receptor Signaling in MASH
Marcelo Icimoto
14:55-15:05
OP.02 | Modeling Human, Rat, and Humanized Bradykinin B2 Receptor-Deucrictibant Complexes In Silico
Niklas Piet Doering
15:05-15:15
OP.03 | Opposing Effects of Kinin B1R and B2R Blockade on Choroidal Neovascularization
Shima Shirzad
15:15-15:45
Coffee Break
15:45-17:05
Session III: Kinin Activities and Regulations
15:45-16:15
Recombinant Tissue Kallikrein
Paolo Maddedu
16:15-16:45
Drug Discovery Strategies for Kallikrein-related Peptidases: From Protease Biology to Therapeutic Intervention
Tobias Dreyer
16:45-16:55
OP.04 | Influence of the Kinin B1 Receptor on Adipocyte Thermogenesis
Jéssica Branquinho
16:55-17:05
OP.05 | From Mechanistic Modeling to Clinical Observation: Plasma Kallikrein Inhibition for Steroid-Refractory Peritumoral Brain Edema
Jeffrey Breit
17:10-17:50
Bus Transfer to Spreespeicher (Location for Scientific Dinner)
18:00-19:00
The E.K. Frey – E. Werle Award Ceremony
Laudation for the Gold Medal Winner
Michael Bader
Gold Medal Talk
19:00-21:30
Scientific Dinner and Quiz
Friday, 4 September 2026
08:00-08:15
Coffee and Welcome
08:15-08:20
Summary Day 1
Michael Bader | Markus Magerl | Thomas Renné
08:20-09:50
Session IV: The Contact System – In Disease States
08:20-08:50
Disarming the Host: A. baumannii Targets the Contact Pathway
Evi Stavrou
08:50-09:20
Intracellular Complement System
Claudia Kemper
09:20-09:30
OP.06 | Lanadelumab Treatment in Factor XII-Associated Cold-Induced Autoinflammatory Syndrome
Hanna Bonnekoh
09:30-09:40
OP.07 | Identification of an Antisense Oligonucleotide Targeting Coagulation Factor XII Expression
João Bosco Pesquero
09:40-09:50
OP.08 | Nocturnal Intermittent Hypoxia-Induced Angioedema: A Novel Concept
Venkata Sasank Donthu
09:50-10:20
Coffee Break
10:20-11:50
Session V: Hereditary Angioedema – Basic Mechanisms
10:20-10:50
Serpin Biochemistry and Engineering
Coen Maas
10:50-11:20
Genome-Wide Association Studies of the KKS and HAE
Steven Grover
11:20-11:30
OP.09 | Whole-Genome Sequencing Reveals Genetic Complexity of SERPING1 in HAE-C1INH
Roger Colobran Oriol
11:30-11:40
OP.10 | Vasoactive Mediators Correlate With Hormonal Fluctuations in Women With C1INH-Hereditary Angioedema
Paola Triggianese
11:40-11:50
OP.11 | Patient-Derived Endothelial Model Recapitulates HAE-MYOF and Kallikrein Inhibitor Response
Yanyan Luo
11:50-12:40
Lunch
12:40-14:40
Session VI: Hereditary Angioedema – Therapies
12:40-13:10
Long-term Prophylaxis in Hereditary Angioedema: From Burden to Breakthrough
Danny Cohn
13:10-13:23
OP.12 | HAELO: Phase 3, Randomized Study of Lonvoguran Ziclumeran in HAE-C1INH
Danny M. Cohn
13:23-13:36
OP.13 | Real-World Experience With Oral Sebetralstat for Hereditary Angioedema Attacks
Thomas Buttgereit
13:36-13:49
OP.14 | Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Regional Subgroup Analysis From the Phase 3 RAPIDe-3 Trial
Marc A. Riedl
13:49-14:02
OP.15 | Donidalorsen for Hereditary Angioedema in Europe: One-Year Patient-Reported Outcomes
Marcin Stobiecki
14:02-14:15
OP.16 | Significant Durable HAE Attack Reduction With BW-20805 – Phase 2 Update
Yuxiang Zhi
14:15-14:28
OP.17 | Disease Control and Patient-Reported Outcomes After Switching to Garadacimab
Petra Staubach
14:28-14:41
OP.18 | Oral Berotralstat Reduces Hereditary Angioedema Attack Rates in Pediatric Patients Without Previous Long-Term Prophylaxis: Interim Data From APeX-P
Emel Aygören-Pürsün
14:41-15:00
Coffee Break
15:00-16:05
Session VII: Hereditary Angioedema – Clinical Topics
15:00-15:25
Recently Described Forms of HAE-nC1INH: Explaining the Clinical Presentations Based on Genetics and Pathophysiology
Matija Rijavec
15:25-15:35
OP.19 | Revisiting Oral Contraception in Hereditary Angioedema: Insights From a Case Series
Mats de Lange
15:35-15:45
OP.20 | Factors Undermining Attack Control in C1-Inhibitor Hereditary Angioedema Older Adults
Francesca Perego
15:45-15:55
OP.21 | From Control to Normalcy: The Hungarian Experience With Novel LTP
Lili Voloncs-Mindszenthy
15:55-16:05
OP.22 | Association Between Hereditary Angioedema and Increased Risk of Bacterial Infections
Linda Sundler Björkman
16:05-16:45
Poster Session
16:45-17:40
Session VIII: HAE Worldwide
16:45-17:10
From Guidelines to Global Impact: Updates to Address Disparities in Hereditary Angioedema Care
Ankur Jindal
17:10-17:20
OP.23 | Determinants of Quality of Life in Hereditary Angioedema: Experience From a Tertiary Care Center in India
Mona Sharma
17:20-17:30
OP.24 | Epidemiological Survey of Bradykinin-Mediated Angioedema: A Preliminary Report From Nepal
Dharmagat Bhattarai
17:30-17:40
OP.25 | Differential Kallikrein Endotypes in African ACE Inhibitor-Induced Angioedema
Sarah Pedretti
17:40-17:55
Conclusion: What did we hear? What do we take home?
Markus Magerl
17:55-18:10
Award Ceremony and Closing Remarks
Michael Bader | Markus Magerl | Thomas Renné
18:10
End of the BRADYKININ Symposium
If you need child care, please contact our professional congress organiser via bradykinin@remember-management.de.
